Please login to the form below

Not currently logged in
Email:
Password:

lisdexamfetamine dimesylate

This page shows the latest lisdexamfetamine dimesylate news and features for those working in and with pharma, biotech and healthcare.

Shire claims FDA approval for slow-cooked ADHD drug

Shire claims FDA approval for slow-cooked ADHD drug

top ADHD seller Vyvanse (lisdexamfetamine dimesylate) - which pulled in $2bn in sales last year, a rise of 17% and added another $563m in the first quarter.

Latest news

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics